Medulloblastoma

Medulloblastoma (MB) is recognized as the most prevalent malignant brain tumor in pediatric patients, comprising approximately 25–30% of all childhood brain tumors. At Alfa Cytology, we are committed to pioneering new therapeutic approaches for medulloblastoma treatment for our clients.

Introduction to Medulloblastoma

Medulloblastoma originates in the cerebellum, specifically in the posterior fossa. The World Health Organization (WHO) classifies MB into four distinct molecular subtypes: WNT, Sonic Hedgehog (SHH), Group 3, and Group 4. Each subtype exhibits unique biological behaviors, prognostic outcomes, and therapeutic responses, making personalized treatment approaches essential.

Fig.1 Molecular features, prognosis, and location of the medulloblastoma subtypes. (Lombardi, G., et al., 2022)

Recent advancements in molecular biology have illuminated the pathogenesis of these subtypes. For instance, WNT medulloblastomas typically feature mutations in the CTNNB1 gene, which encodes β-catenin, leading to the activation of WNT signaling pathways. In contrast, SHH medulloblastomas are associated with alterations in the PTCH1 and SUFU genes, highlighting the role of the Hedgehog signaling pathway in tumor development. Understanding these molecular underpinnings is crucial for developing targeted therapies that can improve clinical outcomes for affected children.

Therapeutic Development for Medulloblastoma

The therapeutic landscape for medulloblastoma has evolved significantly over the past decade. Traditional treatment modalities include surgical resection, radiotherapy, and chemotherapy. However, the advent of molecular profiling has paved the way for innovative therapeutic strategies tailored to the specific subtype of medulloblastoma.

Our Services

At Alfa Cytology, we are dedicated to advancing research and development in the field of medulloblastoma through our comprehensive preclinical services. Our expertise spans molecular profiling, in vivo and in vitro studies, biomarker discovery, and strategic consultation.

• Small Molecule Drug
• Radionuclide Therapy
• Therapeutic Antibody
• Peptide Drug

• Cell Therapy
• Gene Therapy
• Oncolytic Virotherapy
• Vaccine

Therapeutics Development

• Cell Line Development
• Organoids and Organ Chip Models
• Blood Brain Barrier Models

• Xenograft Models
• Syngeneic Models
• Virus-induced Models
• Transgenic Models
• Metastatic Models

Modeling Services

• In Vitro Efficacy Evaluation
• In Vivo Efficacy Evaluation
• In Vitro ADME

• In Vivo PK
• Safety Assessment

Preclinical Research

• Omics Analysis
• Cell Analysis
• Tissue Analysis
• Cytokine Analysis

• Growth Factor Analysis
• Primary Immune Cell Analysis

Diagnostic Development

Contact Us

For more information about our services or to discuss potential collaborations, please contact us at Alfa Cytology. Our team is committed to driving innovation and improving treatment options for medulloblastoma.

Reference

1. Fang, F.Y.; Rosenblum, J.S.; Ho, W.S.; Heiss, J.D. New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of Pediatric Medulloblastoma. Cancers 2022, 14, 2285. Lombardi, G.; et al. (2022). Diagnosis and Treatment of Pineal Region Tumors in Adults: A EURACAN Overview[J]. Cancers. 14, 3646.